This Phase 1 study (ARQ 197–116) was initiated based on the importance and prevalence of MET expression/over-expression in many cancer types and evidence of synergistic inhibition of tivantinib and sorafenib in vivo in several cancer cell lines [10]. The gene discussed is MET; the disease is cancer.